Loading...
•
Jun 30, 2022
scPharmaceuticals Q2 2022 Earnings Report
scPharmaceuticals reported second quarter 2022 financial results and provided a business update.
Key Takeaways
scPharmaceuticals announced FDA acceptance of FUROSCIX® New Drug Application and Prescription Drug User-Fee Act target action date of October 8, 2022. The company ended the second quarter with $56.0 million in cash, cash equivalents, restricted cash and investments. scPharmaceuticals reported a net loss of $9.7 million for the second quarter of 2022.
FDA accepted FUROSCIX NDA with a PDUFA target action date of October 8, 2022.
Advanced commercial readiness activities in anticipation of a Q4 2022 commercial launch of FUROSCIX, if approved.
Announced positive results from the AT HOME-HF Phase 2 Pilot study, showing a 37% reduction in heart failure hospitalization risk with FUROSCIX.
Ended Q2 with cash, cash equivalents, restricted cash and investments of $56.0 million.
Forward Guidance
The Company forecasts its 2022 net loss to be $43 to $48 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...